Shares in health technology group Tempus AI ($TEM) raced 7% higher today after its Q2 revenues surged on cancer testing demand. Forecast Busting ...

In trading on the Nasdaq stock market as of 1:17 p.m. Central, Tempus' stock price was trading at $60.65, up 3.2% from the ...

Tempus AI posts a narrower Q2 loss and an 89.6% revenue surge, driven by genomics growth and new oncology-focused product ...

Tempus AI Inc. (NASDAQ:TEM) reported second-quarter financial results Friday. The AI-focused precision medicine and patient ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

Tempus AI's 10% dip reveals an opportunity as Q2 estimates are poised to exceed expectations, fueled by strong deals and ...

The Tempus AI class action lawsuit further alleges that on May 28, 2025, Spruce Point Capital Management, LLC issued research ...

Tempus AI's growth in precision oncology drives an 80% revenue boost by 2025. Click here to find out why I rate TEM stock a ...

LOS ANGELES, July 28, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Tempus AI, Inc. ("Tempus" or "the ...

Tempus AI Inc. (NASDAQ:TEM) is one of the best AI stocks to buy according to hedge funds. On June 25, Ambry Genetics, which is a wholly owned subsidiary of Tempus AI, announced the publication of ...